SURI
SURI
About Simplify Propel Opportunities ETF
The Simplify Propel Opportunities ETF (SURI) seeks to provide long-term growth of capital by providing investors with exposure to biotech, pharma, health care technology, and life science companies that are believed to be overlooked by investors, thereby presenting significant opportunities for capital appreciation. The fund is sub-advised by Propel, which uses its deep scientific and commercial...
About Simplify Propel Opportunities ETF
The Simplify Propel Opportunities ETF (SURI) seeks to provide long-term growth of capital by providing investors with exposure to biotech, pharma, health care technology, and life science companies that are believed to be overlooked by investors, thereby presenting significant opportunities for capital appreciation. The fund is sub-advised by Propel, which uses its deep scientific and commercial...
HOLDINGS (Top 20)
| Stock | Name | Weight | Shares | Market Value |
|---|---|---|---|---|
 PAGP | Plains GP Holdings, L.P. | 31.51% | 1.27M | $24.43M |
 ACHV | Achieve Life Sciences, Inc. | 7.95% | 1.18M | $6.16M |
 PHAT | Phathom Pharmaceuticals, Inc. | 7.51% | 321.94K | $5.82M |
 MIST | Milestone Pharmaceuticals Inc. | 4.18% | 1.51M | $3.24M |
 VRDN | Viridian Therapeutics, Inc. | 4.08% | 103.53K | $3.16M |
 DCTH | Delcath Systems, Inc. | 3.55% | 261.13K | $2.75M |
 ABEO | Abeona Therapeutics Inc. | 3.37% | 500.34K | $2.61M |
 CLDX | Celldex Therapeutics, Inc. | 3.04% | 85.00K | $2.36M |
 CMPS | COMPASS Pathways plc | 2.93% | 290.00K | $2.27M |
 OCS | Oculis Holding AG | 2.67% | 98.77K | $2.07M |
 IVA | Inventiva S.A. | 2.22% | 337.66K | $1.72M |
 KYTX | Kyverna Therapeutics, Inc. | 2.16% | 192.34K | $1.67M |
 NKTR | Nektar Therapeutics | 1.57% | 28.00K | $1.22M |
 ATHA | Athira Pharma, Inc. | 1.41% | 149.28K | $1.09M |
 SABS | SAB Biotherapeutics, Inc. | 1.07% | 208.23K | $826.66K |
 RGNX | REGENXBIO Inc. | 0.75% | 38.00K | $579.12K |
 ZVRA | Zevra Therapeutics, Inc. | 0.41% | 37.82K | $320.72K |
 LENZ | LENZ Therapeutics, Inc. | 0.37% | 17.48K | $285.12K |
 QNRX | Quoin Pharmaceuticals, Ltd. | 0.31% | 17.45K | $239.91K |
 KLRS | Kalaris Therapeutics Inc | 0.23% | 20.07K | $175.85K |
SECTOR HOLDINGS
Healthcare
EnergyASSET ALLOCATION BY REGION
United States
Canada
Switzerland
United Kingdom
FranceSECTOR HOLDINGS
Healthcare EnergyASSET ALLOCATION BY REGION
United States Canada Switzerland United Kingdom FranceHoldings (Top 20)
PAGP
Plains GP Holdings, L.P.
ACHV
Achieve Life Sciences, Inc.
PHAT
Phathom Pharmaceuticals, Inc.
MIST
Milestone Pharmaceuticals Inc.
VRDN
Viridian Therapeutics, Inc.
DCTH
Delcath Systems, Inc.
ABEO
Abeona Therapeutics Inc.
CLDX
Celldex Therapeutics, Inc.
CMPS
COMPASS Pathways plc
OCS
Oculis Holding AG
IVA
Inventiva S.A.
KYTX
Kyverna Therapeutics, Inc.
NKTR
Nektar Therapeutics
ATHA
Athira Pharma, Inc.
SABS
SAB Biotherapeutics, Inc.
RGNX
REGENXBIO Inc.
ZVRA
Zevra Therapeutics, Inc.
LENZ
LENZ Therapeutics, Inc.
QNRX
Quoin Pharmaceuticals, Ltd.
KLRS
Kalaris Therapeutics Inc